Biopharma Adoptive NK Cell Therapies sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma Adoptive NK Cell Therapies
1.1 - About Biopharma Adoptive NK Cell Therapies sector
Companies in Biopharma Adoptive NK Cell Therapies develop and manufacture natural killer cell–based immunotherapies, delivering allogeneic and engineered cell products for hematologic malignancies and solid tumors. They combine proprietary NK platforms with scalable GMP production to provide off‑the‑shelf doses, clinical trial supply, and translational support. The value proposition centers on rapid availability, potential safety advantages, and combinability with antibodies and engagers to improve patient outcomes.
These companies typically offer iPSC‑derived and cord blood/peripheral blood NK cell lines, CAR‑NK engineering, feeder‑based and cytokine (IL‑15) expansion systems, and CRISPR gene editing to enhance persistence and cytotoxicity. They operate GMP suites for activation, formulation, cryopreservation, and release testing, with potency and immune monitoring assays. Strategic buyers in adoptive NK cell therapy also provide clinical trial sponsorship, regulatory CMC, cold‑chain logistics, and combination regimens with monoclonal antibodies or NK cell engagers.
Primary customers include oncology clinics and hospital cellular therapy programs administering investigational products, as well as biopharma partners and academic cancer centers co‑developing assets. Outcomes delivered include broader patient access through off‑the‑shelf dosing, shorter vein‑to‑vein timelines, improved safety management versus T‑cell therapies in certain settings, and scalable manufacturing that supports faster trial enrollment and pipeline expansion across hematologic malignancies and selected solid tumor indications.
2. Buyers in the Biopharma Adoptive NK Cell Therapies sector
2.1 Top strategic acquirers of Biopharma Adoptive NK Cell Therapies companies
Nkarta
- Description: Provider of off-the-shelf, allogeneic chimeric antigen receptor (NK) cell therapies for cancer, applying proprietary NK cell expansion and engineering platforms to harness natural killer cell cytotoxicity. Its pipeline includes lead candidates NKX101 and NKX201 for acute myeloid leukemia and other hematologic malignancies, supported by scalable manufacturing processes to rapidly deliver broadly applicable cellular immunotherapies.
- Key Products:
- Allogeneic NK Cell Therapy Platform: Expands and cryopreserves donor-derived NK cells, then engineers them to improve tumor targeting and cell persistence, enabling scalable off-the-shelf cancer treatments
- Engineered NK Cell Therapy Candidates Pipeline: Manufactures investigational NK cell products through efficient processes to deliver sustained anti-tumor activity and potentially reset immune balance in autoimmune disorders
- Ntrust-1 Investigational Therapy: Next-generation NK cell treatment being studied for safety and activity in lupus nephritis, designed to address the disease’s root cause rather than merely control symptoms
- Ntrust-2 Investigational Therapy: Differently engineered NK cell therapy under evaluation for systemic sclerosis, myositis and vasculitis, aiming to reach the underlying mechanisms of these autoimmune diseases for durable benefit.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma Adoptive NK Cell Therapies sector
M&A buyer group 1: Cell Therapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma Adoptive NK Cell Therapies sector
3.1 - Buyout funds in the Biopharma Adoptive NK Cell Therapies sector
2.2 - Strategic buyer groups for Biopharma Adoptive NK Cell Therapies sector
4 - Top valuation comps for Biopharma Adoptive NK Cell Therapies companies
4.2 - Public trading comparable groups for Biopharma Adoptive NK Cell Therapies sector
Valuation benchmark group 1: Cell and Gene Therapy Biopharma Companies
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions